UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Primary hyperparathyroidism: Clinical manifestations

Authors
Ghada El-Hajj Fuleihan, MD, MPH
Shonni J Silverberg, MD
Section Editor
Clifford J Rosen, MD
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

The most common clinical presentation of primary hyperparathyroidism (PHPT) is asymptomatic hypercalcemia detected by routine biochemical screening. However, the presentation may be atypical and include a spectrum of disturbances in calcium homeostasis, ranging from symptomatic severe hypercalcemia (parathyroid crisis) to normocalcemic PHPT.

The clinical manifestations that are directly related to PHPT will be reviewed here. Symptoms and signs (gastrointestinal, neuromuscular, renal, and psychological) that are likely related to hypercalcemia are also discussed elsewhere (see "Clinical manifestations of hypercalcemia"). It should be recognized, however, that the distinction is to some extent arbitrary.

The clinical manifestations of the familial forms of PHPT and of parathyroid cancer, and the diagnosis and management of PHPT, are also reviewed separately.

(See "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis".)

(See "Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2".)

                             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Apr 29 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:2036.
  2. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350:1746.
  3. Siperstein AE, Shen W, Chan AK, et al. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery. Arch Surg 1992; 127:1157.
  4. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341:1249.
  5. Yu N, Leese GP, Smith D, Donnan PT. The natural history of treated and untreated primary hyperparathyroidism: the parathyroid epidemiology and audit research study. QJM 2011; 104:513.
  6. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93:3462.
  7. Perrier ND. Asymptomatic hyperparathyroidism: a medical misnomer? Surgery 2005; 137:127.
  8. Lundgren E, Szabo E, Ljunghall S, et al. Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism. BMJ 1998; 317:848.
  9. Lundgren E, Ljunghall S, Akerström G, et al. Case-control study on symptoms and signs of "asymptomatic" primary hyperparathyroidism. Surgery 1998; 124:980.
  10. Chan AK, Duh QY, Katz MH, et al. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg 1995; 222:402.
  11. Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:351.
  12. Silverberg SJ, Bilezikian JP. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. J Clin Endocrinol Metab 2003; 88:5348.
  13. Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med 2004; 117:861.
  14. Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007; 92:3001.
  15. Corlew DS, Bryda SL, Bradley EL 3rd, DiGirolamo M. Observations on the course of untreated primary hyperparathyroidism. Surgery 1985; 98:1064.
  16. Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism. 10-year prospective study. Mayo Clin Proc 1981; 56:473.
  17. Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. Am J Med 2015; 128:239.
  18. Fitzpatrick LA, Bilezikian JP. Acute primary hyperparathyroidism. Am J Med 1987; 82:275.
  19. Bondeson AG, Bondeson L, Thompson NW. Clinicopathological peculiarities in parathyroid disease with hypercalcaemic crisis. Eur J Surg 1993; 159:613.
  20. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005; 257:6.
  21. Harrison BJ, Wheeler MH. Asymptomatic primary hyperparathyroidism. World J Surg 1991; 15:724.
  22. Gopal RA, Acharya SV, Bandgar T, et al. Clinical profile of primary hyperparathyroidism from western India: a single center experience. J Postgrad Med 2010; 56:79.
  23. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities--New York and Beijing. Int J Fertil Womens Med 2000; 45:158.
  24. Mishra SK, Agarwal G, Kar DK, et al. Unique clinical characteristics of primary hyperparathyroidism in India. Br J Surg 2001; 88:708.
  25. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3561.
  26. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3580.
  27. Boudou P, Ibrahim F, Cormier C, et al. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006; 29:511.
  28. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000; 85:1054.
  29. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999; 107:561.
  30. Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sestamibi scan. Arch Otolaryngol Head Neck Surg 2008; 134:1071.
  31. Bilezikian JP, Silverberg SJ, Shane E, et al. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991; 6 Suppl 2:S85.
  32. Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res 2002; 17 Suppl 2:N87.
  33. Parks J, Coe F, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140:1479.
  34. Yendt ER, Gagne RJ. Detection of primary hyperparathyroidism, with special reference to its occurrence in hypercalciuric females with "normal" or borderline serum calcium. Can Med Assoc J 1968; 98:331.
  35. Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 1992; 90:749.
  36. Broadus AE, Horst RL, Lang R, et al. The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Engl J Med 1980; 302:421.
  37. Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med 1990; 89:327.
  38. Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore) 1974; 53:127.
  39. Patten BM, Bilezikian JP, Mallette LE, et al. Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 1974; 80:182.
  40. Turken SA, Cafferty M, Silverberg SJ, et al. Neuromuscular involvement in mild, asymptomatic primary hyperparathyroidism. Am J Med 1989; 87:553.
  41. Chou FF, Sheen-Chen SM, Leong CP. Neuromuscular recovery after parathyroidectomy in primary hyperparathyroidism. Surgery 1995; 117:18.
  42. McAllion SJ, Paterson CR. Psychiatric morbidity in primary hyperparathyroidism. Postgrad Med J 1989; 65:628.
  43. Joborn C, Hetta J, Johansson H, et al. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 1988; 12:476.
  44. Coker LH, Rorie K, Cantley L, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Ann Surg 2005; 242:642.
  45. Walker MD, McMahon DJ, Inabnet WB, et al. Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009; 94:1951.
  46. Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 2007; 92:1687.
  47. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 2007; 92:3114.
  48. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 2004; 89:5415.
  49. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 1989; 4:283.
  50. Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997; 21:93.
  51. Abdelhadi M, Nordenström J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:3845.
  52. Parisien M, Mellish RW, Silverberg SJ, et al. Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res 1992; 7:913.
  53. Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone 2011; 48:557.
  54. De Geronimo S, Romagnoli E, Diacinti D, et al. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol 2006; 155:415.
  55. Dauphine RT, Riggs BL, Scholz DA. Back pain and vertebral crush fractures: an unemphasized mode of presentation for primary hyperparathyroidism. Ann Intern Med 1975; 83:365.
  56. Kenny AM, MacGillivray DC, Pilbeam CC, et al. Fracture incidence in postmenopausal women with primary hyperparathyroidism. Surgery 1995; 118:109.
  57. Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Heath H 3rd. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med 1992; 152:2269.
  58. Khosla S, Melton LJ 3rd, Wermers RA, et al. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999; 14:1700.
  59. Khosla S, Melton J 3rd. Fracture risk in primary hyperparathyroidism. J Bone Miner Res 2002; 17 Suppl 2:N103.
  60. Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:2306.
  61. Wilson RJ, Rao S, Ellis B, et al. Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. Ann Intern Med 1988; 109:959.
  62. Hansen S, Beck Jensen JE, Rasmussen L, et al. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT. J Bone Miner Res 2010; 25:1941.
  63. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res 2013; 28:1029.
  64. Vu TD, Wang XF, Wang Q, et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone 2013; 55:57.
  65. Larsson K, Ljunghall S, Krusemo UB, et al. The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 1993; 234:585.
  66. Tassone F, Gianotti L, Emmolo I, et al. Glomerular filtration rate and parathyroid hormone secretion in primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:4458.
  67. Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 2011; 96:2377.
  68. Suh JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 2008; 191:908.
  69. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease--a review. Eur Heart J 2004; 25:1776.
  70. Lind L, Hvarfner A, Palmér M, et al. Hypertension in primary hyperparathyroidism in relation to histopathology. Eur J Surg 1991; 157:457.
  71. Lind L, Ljunghall S. Pre-operative evaluation of risk factors for complications in patients with primary hyperparathyroidism. Eur J Clin Invest 1995; 25:955.
  72. Lind L, Jacobsson S, Palmér M, et al. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230:29.
  73. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997; 82:106.
  74. Näppi S, Saha H, Virtanen V, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology 2000; 93:229.
  75. Nilsson IL, Aberg J, Rastad J, Lind L. Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism-effects of parathyroidectomy. Surgery 2000; 128:895.
  76. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999; 50:321.
  77. Barletta G, De Feo ML, Del Bene R, et al. Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:1815.
  78. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2010; 95:2172.
  79. Smith JC, Page MD, John R, et al. Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85:3515.
  80. Rubin MR, Maurer MS, McMahon DJ, et al. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:3326.
  81. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab 2009; 94:3849.
  82. Procopio M, Magro G, Cesario F, et al. The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med 2002; 19:958.
  83. Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med 1998; 244:241.
  84. Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005; 90:1525.
  85. Rubin MR, Silverberg SJ, Bilezikian JP. Primary hyperparathyroidism: Rheumatologic manifestations and bone disease. In: Bone Disease in Rheumatology, Maricic M, Gluck OS (Eds), Lippincott Williams & Wilkins, Philadelphia 2005. p.190.
  86. Helliwell M. [Rheumatic symptoms in primary hyperparathyroidism]. Postgrad Med J 1983; 59:236.
  87. Bilezikian JP, Connor TB, Aptekar R, et al. Pseudogout after parathyroidectomy. Lancet 1973; 1:445.
  88. Rynes RI, Merzig EG. Calcium pyrophosphate crystal deposition disease and hyperparathyroidism: a controlled, prospective study. J Rheumatol 1978; 5:460.
  89. Alexander GM, Dieppe PA, Doherty M, Scott DG. Pyrophosphate arthropathy: a study of metabolic associations and laboratory data. Ann Rheum Dis 1982; 41:377.
  90. Hulter HN, Peterson JC. Acid-base homeostasis during chronic PTH excess in humans. Kidney Int 1985; 28:187.
  91. Sutton RA, Wong NL, Dirks JH. Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. Kidney Int 1979; 15:520.
  92. Boxer M, Ellman L, Geller R, Wang CA. Anemia in primary hyperparathyroidism. Arch Intern Med 1977; 137:588.
  93. Meytes D, Bogin E, Ma A, et al. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981; 67:1263.
  94. Johansson H, Werner I. Letter: Dysproteinemia, malignancy, and hyperparathyroidism. Ann Intern Med 1975; 83:121.
  95. Mundis RJ, Kyle RA. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 1982; 77:619.
  96. Rao DS, Antonelli R, Kane KR, et al. Primary hyperparathyroidism and monoclonal gammopathy. Henry Ford Hosp Med J 1991; 39:41.
  97. Arnulf B, Bengoufa D, Sarfati E, et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med 2002; 162:464.
  98. Nilsson IL, Yin L, Lundgren E, et al. Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res 2002; 17 Suppl 2:N68.
  99. Wermers RA, Khosla S, Atkinson EJ, et al. Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998; 104:115.
  100. Palmér M, Adami HO, Krusemo UB, Ljunghall S. Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol 1988; 127:1031.
  101. Pickard AL, Gridley G, Mellemkjae L, et al. Hyperparathyroidism and subsequent cancer risk in Denmark. Cancer 2002; 95:1611.
  102. Michels KB, Xue F, Brandt L, Ekbom A. Hyperparathyroidism and subsequent incidence of breast cancer. Int J Cancer 2004; 110:449.
  103. Tanaka Y. Primary hyperparathyroidism with breast carcinoma. Breast Cancer 2010; 17:265.
  104. Palmer M, Adami HO, Bergström R, et al. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987; 1:59.
  105. Leifsson BG, Ahrén B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996; 81:2149.
  106. Hedbäck G, Odén A. Increased risk of death from primary hyperparathyroidism--an update. Eur J Clin Invest 1998; 28:271.
  107. Hedbäck G, Tisell LE, Bengtsson BA, et al. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 1990; 14:829.
  108. Palmér M, Adami HO, Bergström R, et al. Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987; 102:1.
  109. Lundgren E, Lind L, Palmér M, et al. Increased cardiovascular mortality and normalized serum calcium in patients with mild hypercalcemia followed up for 25 years. Surgery 2001; 130:978.
  110. Clifton-Bligh PB, Nery ML, Supramaniam R, et al. Mortality associated with primary hyperparathyroidism. Bone 2015; 74:121.
  111. Söreide JA, van Heerden JA, Grant CS, et al. Survival after surgical treatment for primary hyperparathyroidism. Surgery 1997; 122:1117.
  112. Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011; 75:169.